mupirocin 20 mg/g Ointment, 1 g
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the RNA Synthetase Inhibitor Antibacterial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Mupirocin, an antibiotic, is used to treat impetigo as well as other skin infections caused by bacteria. It is not effective against fungal or viral infections. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Read the full MedlinePlus article ↗- Mupirocin is a topical antibiotic — meaning it's applied directly to the skin. The ointment form is used to treat impetigo, which is a contagious bacterial skin infection common in...
- Apply a small amount — about the size of a pea — to the affected area three times a day using a cotton swab or gauze pad. You can cover the area with a gauze dressing if you'd like...
- How do I apply it, and how long do I use it?
- Most people do just fine with mupirocin. The most common side effects are headache, nausea, rash, and a little burning or itching where you applied it. Those are usually mild and g...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Mupirocin — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3WJQ0SDW1A
Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.3533 | $0.35 / 1 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Mupirocin 20 mg/g 00093-1010-42 | Teva | 1 tube | $0.145 | AB | Availability likely | — |
| Mupirocin 20 mg/g 51672-1312-00 | Sun | 1 tube | $0.145 | AB | Availability likely | — |
| Mupirocin 20 mg/g 68462-0180-22 | Glenmark | 22 g | $0.145 | AB | Availability likely | — |
| Mupirocin 20 mg/g 21922-0073-04 | Encube | 1 tube | $0.299 | AB | Availability likely | — |
| mupirocin 20 mg/g 45802-0112-14 | Padagis | 1 tube | $0.299 | AB | Availability likely | — |
| Mupirocin 20 mg/g 00121-1076-00 | PAI | 100 tubes | — | AB | FDA listed | — |
| mupirocin 20 mg/gthis 17856-0112-01 | ATLANTIC | 1 g | — | AB | FDA listed | — |
| mupirocin 20 mg/g 50090-1587-00 | A-S | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 50268-0568-15 | AvPAK | 50 tubes | — | AB | FDA listed | — |
| mupirocin 20 mg/g 60760-0960-22 | St. | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 61919-0158-22 | DIRECT | 20 g | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 63187-0015-22 | Proficient | 22 g | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 63187-0151-22 | Proficient | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 63187-0261-22 | Proficient | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 63187-0525-22 | Proficient | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 63629-8687-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 67296-2211-01 | Redpharm | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 68071-4111-02 | NuCare | 22 g | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 68071-4321-02 | NuCare | 22 g | — | AB | FDA listed | — |
| mupirocin 20 mg/g 68071-4789-02 | NuCare | 22 g | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 68788-8534-02 | Preferred | 22 g | — | AB | FDA listed | — |
| mupirocin 20 mg/g 68788-8642-02 | Preferred | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 70166-0355-10 | Lohxa | 100 tubes | — | AB | FDA listed | — |
| mupirocin 20 mg/g 70518-1808-00 | REMEDYREPACK | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 71335-2829-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 72162-2270-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 76420-0128-22 | Asclemed | 22 g | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 80425-0246-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 80425-0254-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 81033-0032-50 | Kesin | 50 tubes | — | AB | FDA listed | — |
| Mupirocin 20 mg/g 85766-0207-15 | Sportpharm | 1 tube | — | AB | FDA listed | — |
| mupirocin 20 mg/g 85534-0038-00 | HAWAII | 1 tube | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 17856-0112-01 You're viewing this | 1 g in 1 SYRINGE (17856-0112-1) | 2024-05-08 | Active |
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: and . S. aureus S. pyogenes
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION A small amount of Mupirocin Ointment USP, 2% should be applied to the affected area 3 times daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.
⛔ Contraindications ▾
CONTRAINDICATIONS This drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.
⚠️ Warnings ▾
WARNINGS Avoid contact with the eyes. In case of accidental contact, rinse well with water. In the event of sensitization or severe local irritation from Mupirocin Ointment USP, 2%, usage should be discontinued. - associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including mupirocin, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of . Clostridium difficile C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing isolates of cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. C. difficile C. difficile If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of , and surgical evaluation should be instituted as clinically indicated. C. difficile C. difficile
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions have been reported in connection with the use of mupirocin ointment USP, 2%: burning, stinging, or pain in 1.5% of subjects; itching in 1% of subjects; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of subjects. Systemic allergic reactions, including anaphylaxis, urticaria, angioedema and generalized rash have been reported in patients treated with mupirocin formulations.
🔄 Drug Interactions ▾
- Drug Interactions The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects: Pregnancy Category B - Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) on a mg/m basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
2
🧒 Pediatric Use ▾
Pediatric Use - The safety and effectiveness of Mupirocin Ointment USP, 2% have been established in the age range of 2 months to 16 years. Use of mupirocin ointment USP, 2% in these age groups is supported by evidence from adequate and well-controlled trials of mupirocin ointment USP, 2% in impetigo in pediatric subjects studied as part of the pivotal clinical trials (see ). CLINICAL STUDIES
Pediatrics - There were 91 pediatric subjects aged 2 months to 15 years in the first trial described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for mupirocin ointment USP, 2% (n=42) and 36% for vehicle placebo (n=49). In the second trial described above, all subjects were pediatric except 2 adults in the group receiving mupirocin ointment USP, 2%.
The age range of the pediatric subjects was 7 months to 13 years. The clinical efficacy rate for mupirocin ointment USP, 2% (n=27) was 96%, and for erythromycin it was unchanged (78.5%).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Application of C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (<1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application. 14 Following intravenous or oral administration, mupirocin is rapidly metabolized.
The principal metabolite, monic acid, is eliminated by renal excretion, and demonstrates no antibacterial activity. In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. The pharmacokinetics of mupirocin has not been studied in individuals with renal insufficiency.
Microbiology - Mupirocin is an antibacterial agent produced by fermentation using the organism . Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA (tRNA) synthetase. Due to this unique mode of action, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents.
Pseudomonas fluorescens When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC >512 mcg/mL) has been reported in increasing numbers of isolates of and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci.
Because of the occurrence of mupirocin resistance in methicillin-resistant (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method. Staphylococcus aureus Staphylococcus aureu 1 ,2,3 Mupirocin is bactericidal at concentrations achieved by topical administration. Mupirocin is highly protein-bound (>97%), and the effect of wound secretions on the MICs of mupirocin has not been determined.
Mupirocin has been shown to be active against susceptible strains of , both and in clinical trials (see INDICATIONS AND USAGE). The following data are available, . Mupirocin is active against most isolates of .
S. aureus and Streptococcus pyogenes in vitro in vitro but their clinical significance is unknown Staphylococcus epidermidis
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED NDC:17856-0112-1 in a SYRINGE of 1 OINTMENTS
📋 Description ▾
DESCRIPTION Each gram of Mupirocin Ointment USP, 2% contains 20 mg mupirocin in a bland water miscible ointment base (polyethylene glycol ointment, NF) consisting of polyethylene glycol 400 and polyethylene glycol 3350. Mupirocin is a naturally occurring antibiotic. The chemical name is ( )-(2 ,3 ,4 ,5 )-5-[(2 ,3 ,4 ,5 )-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2 -pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid.
The molecular formula of mupirocin is C H O and the molecular weight is 500.62. E S R R S S S S S H 26 44 9 The chemical structure is: CHEMICAL STRUCTURE
💬 Information for Patients ▾
Information for Patients - Use this medication only as directed by the healthcare provider. It is for external use only. Avoid contact with the eyes.
If Mupirocin Ointment USP, 2% gets in or near the eyes, rinse thoroughly with water. The medication should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs. If impetigo has not improved in 3 to 5 days, contact the healthcare provider. - Drug Interactions The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied.